CHRS vs HBAN · rev $26.6M vs P/E 13, rev $1.56B
Coherus BioSciences Inc (CHRS) versus Huntington Bancshares Incorporated (HBAN) — a side-by-side from cached financials, not a winner call.
Coherus BioSciences Inc (CHRS) is a biotechnology company listed on US.
Huntington Bancshares Incorporated (HBAN) is a banks - regional company listed on US.
Latest reported CHRS revenue for 2026-06-30 was $26.6M. Net income was -$59.0M. CHRS currently screens at market cap $223.7M.
Latest reported HBAN revenue for 2025-12-31 was $1.56B. Net income was $2.21B. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. HBAN currently screens at market cap $25.55B and trailing P/E 13.5.
CHRS currently screens at market cap $223.7M. HBAN currently screens at market cap $25.55B and trailing P/E 13.5.
Not investment advice. Open the CHRS and HBAN stock pages for the full models.
Not investment advice.